Investigational Drugs
Investigational drugs for NAFLD are derived from global clinical trials with the latest progress, and detailed drug properties are extracted from DrugBank and PubChem. For each drug, related therapeutic strategies, targets, and clinical trials in NAFLDkb are presented with knowledge graphs.
stats1
stats2
Search for:
FXR24 records.
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D078 | Cilofexor | Chemical drug | DB15168 | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| D117 | EDP-305 | Chemical drug | -- | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| D130 | EYP001a | Chemical drug | -- | FXR agonist;FXR modulator | Enhance lipid metabolism | Under clinical trials | Details |
| D184 | INT-767 | Chemical drug | -- | FXR agonist; TGR5 agonist | Enhance lipid metabolism | Under investigation | Details |
| D241 | Nidufexor | Chemical drug | DB16255 | FXR modulator | Enhance lipid metabolism | Under clinical trials | Details |
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D250 | Odevixibat | Chemical drug | DB16261 | SLC10A2 inhibitor; ASBT inhibitor | -- | Under clinical trials | Details |
| D362 | TERN-101 | Chemical drug | DB16045 | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| D365 | TEV-45478 | Biological drug | -- | -- | -- | Under clinical trials | Details |
| D379 | Tropifexor | Chemical drug | DB16343 | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| D415 | Tropifexor plus Licogliflozin | Combinatory | -- | FXR agonist & SGLTs inhibitor | -- | Under clinical trials | Details |
| D416 | Tropifexor plus Cenicriviroc | Combinatory | -- | FXR agonist & CCR2/5 antagonist | -- | Under clinical trials | Details |
| D417 | Tropifexor plus LYS006 | Combinatory | -- | FXR agonist & leukotriene A4 hydrolase inhibitor | -- | Under clinical trials | Details |
| D418 | MET409 plus Empagliflozin | Combinatory | -- | FXR agonist & Sodium-glucose cotransporter 2 inhibitors (SGLT2i) | -- | Under clinical trials | Details |
| D444 | Obeticholic acid plus Atorvastatin | Combinatory | -- | FXR agonist & HMG CoA reductase inhibitor | -- | Under clinical trials | Details |
| D448 | Semaglutide + Cilofexor + Firsocostat | Combinatory | -- | GLP1 receptor agonist & FXR agonist & ACC inhibitor | -- | Under clinical trials | Details |
| D449 | Semaglutide + (Cilofexor or/and Firsocostat) | Combinatory | -- | GLP1 receptor agonist & FXR agonist & ACC inhibitor | -- | Under clinical trials | Details |
| D450 | Selonsertib + Firsocostat + Cilofexor | Combinatory | -- | ASK1 inhibitor & ACC inhibitor & FXR agonist | -- | Under clinical trials | Details |
| D451 | Selonsertib + Firsocostat, Cilofexor, Fenofibrate or Vascepa | Combinatory | -- | ASK1 inhibitor & ACC inhibitor & FXR agonist & PPAR-α activator & icosapent ethyl | -- | Under clinical trials | Details |
| D470 | BAR502 | Chemical drug | -- | dual GPBAR1 and FXR agonist | -- | Under clinical trials | Details |
| D492 | EDP-297 | Chemical drug | -- | FXR agonist | Anti-fibrotic effects | Under clinical trials | Details |
| D493 | MET642 | Chemical drug | -- | FXR agonist | -- | Under clinical trials | Details |
| D515 | XZP-5610 | Chemical drug | -- | FXR agonist | -- | Under clinical trials | Details |
| D580 | Tiliamsoine | Miscellany | -- | FXR agonist | Enhance lipid metabolism | Under investigation | Details |